These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28711777)

  • 1. Comment on: "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome".
    Yazici A; Unlu O; Erkan D
    Thromb Res; 2017 Sep; 157():82-83. PubMed ID: 28711777
    [No Abstract]   [Full Text] [Related]  

  • 2. [Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report].
    Joalland F; de Boysson H; Darnige L; Johnson A; Jeanjean C; Cheze S; Augustin A; Auzary C; Geffray L
    Rev Med Interne; 2014 Nov; 35(11):752-6. PubMed ID: 25217794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid syndrome and direct oral anticoagulants: to the future and back again?
    Wahl D
    Br J Haematol; 2020 Apr; 189(2):210-211. PubMed ID: 31960410
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
    Noel N; Dutasta F; Costedoat-Chalumeau N; Bienvenu B; Mariette X; Geffray L; Sene D; Chaidi RB; Michot JM; Fain O; Darnige L; Ankri A; Cacoub P; Piette JC; Saadoun D
    Autoimmun Rev; 2015 Aug; 14(8):680-5. PubMed ID: 25864630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants.
    Arachchillage DRJ; Gomez K; Alikhan R; Anderson JAM; Lester W; Laffan M;
    Br J Haematol; 2020 Apr; 189(2):212-215. PubMed ID: 31943138
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
    Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
    Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome.
    Scanvion Q; Morell-Dubois S; Yelnik CM; Bene J; Gautier S; Lambert M
    Rheumatology (Oxford); 2018 May; 57(5):938-939. PubMed ID: 29373704
    [No Abstract]   [Full Text] [Related]  

  • 8. Intensity and duration of oral anticoagulation in antiphospholipid antibody associated thrombosis.
    Hunt BJ; Khamashta MA
    J Rheumatol; 2002 Nov; 29(11):2468; author reply 2468-70. PubMed ID: 12415613
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply.
    Dufrost V; Risse J; Wahl D; Zuily S
    Rheumatology (Oxford); 2018 May; 57(5):939-940. PubMed ID: 29373692
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring oral anticoagulation may require determination of single coagulation factor activities in patients with antiphospholipid syndrome.
    Sucker C; Wenzel F; Zotz RB; Hetzel GR; Scharf RE
    J Rheumatol; 2006 Sep; 33(9):1881-2. PubMed ID: 16881092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal: Ischemic gastrointestinal manifestations in a young adult: Implicating a rare initial presentation of antiphospholipid syndrome.
    Senatore FJ; McDonald K
    J Gastroenterol Hepatol; 2016 Aug; 31(8):1381. PubMed ID: 27029604
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment.
    Dufrost V; Risse J; Wahl D; Zuily S
    Curr Rheumatol Rep; 2017 Aug; 19(8):52. PubMed ID: 28741234
    [No Abstract]   [Full Text] [Related]  

  • 13. Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?
    Thachil J
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):82-4. PubMed ID: 23103726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of oral anticoagulants in antiphospholipid syndrome.
    Espinosa G; Coloma Bazán E; Cervera R
    Lupus; 2017 Oct; 26(12):1347-1348. PubMed ID: 28467292
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
    Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
    Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in antiphospholipid syndrome.
    Carvalho JF; Andrade DC; Levy RA
    Rev Bras Reumatol Engl Ed; 2016; 56(6):469-470. PubMed ID: 27914591
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to: "Monitoring antivitamin K anticoagulants in antiphospholipid syndrome: A challenge in quality".
    Pastori D; Parrotto S; Vicario T; Saliola M; Mezzaroma I; Violi F; Pignatelli P
    Atherosclerosis; 2017 Jan; 256():148-149. PubMed ID: 27993386
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Leong D; Wu PE
    Ann Intern Med; 2020 Apr; 172(7):509-510. PubMed ID: 32252074
    [No Abstract]   [Full Text] [Related]  

  • 20. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
    Moll S
    Ann Intern Med; 2020 Apr; 172(7):510. PubMed ID: 32252075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.